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ABSTRACT 
Adult patients suffering from liver disease of unknown cause represent an 
understudied and underserved population. Over the past 15 years, next-
generation sequencing technologies have matured into an inexpensive, effective, 
and widely available set of tools to do genomic analysis. One of these 
technologies, whole-exome sequencing (WES), allows for high throughput 
sequencing of all of the genome’s protein coding regions (exons). In pediatric 
cohorts, WES combined with deep clinical phenotyping has been shown to be an 
effective and unbiased method of identifying rare protein-altering coding variants 
in individual genes. WES has also contributed to the diagnosis and 
individualization of medical care in oncologic patients. The use of WES for the 
study of a broader spectrum of non-oncological diseases, among adults, remains 
poorly understood. We assessed the utility of WES in the diagnosis and 
management of adults with unexplained liver disease despite a comprehensive 
conventional workup and with no history of alcohol overuse.  
We performed exome sequencing and deep phenotyping in two independent 
adult cohorts with unexplained liver disease. In the first cohort, we analyzed 
nineteen unrelated adult patients with idiopathic liver disease recruited at Yale 
New Haven Hospital. In a second cohort from Bridgeport Hospital, four unrelated 
adult patients presenting with fatty liver disease, hypertriglyceridemia, insulin 
resistance, and physical exam findings suggestive of lipodystrophy were 
recruited for genomic analysis. 
In cohort 1, analysis of the exome in nineteen cases identified four monogenic 
disorders in five unrelated adults. Patient 1 suffered for 18 years from 
devastating complications of undiagnosed Type 3 Familial Partial Lipodystrophy 
due to a deleterious heterozygous variant in PPARG. Molecular diagnosis 
enabled initiation of leptin replacement therapy with subsequent normalization of 
liver transaminases, and amelioration of dyslipidemia. Patients 2 and 3 were 
diagnosed with MDR3 deficiency (also known as PFIC3, progressive intrahepatic 
familial cholestasis type 3) due to recessive mutations in ABCB4. Patient 4 with a 
prior diagnosis of non-alcoholic steatohepatitis was found to harbor a 
mitochondrial disorder due to a homozygous pathogenic variant in NDUFB3; 
subsequent muscle biopsy revealed a deficiency of rotenone sensitive I+III 
activity consistent with a mitochondrial disorder. This finding enabled initiation of 
disease-preventative measures including supplementation with antioxidants. 
Patient 5 is a lean patient with hepatic steatosis of unknown etiology who was 
found to have a damaging heterozygous variant in APOB, consistent with familial 
hypobetalipoproteinemia. In cohort 2, we identified a potential genetic diagnosis 
in all four cases of suspected lipodystrophy, including a patient with an LMNA 
mutation, a patient with two pathogenic heterozygous mutations in APOE, a 
patient with a homozygous deleterious mutation in the leptin receptor (LEPR), 
and a patient with a pathogenic heterozygous variant in PPARG.  
In conclusion, WES provided a diagnosis with impact on clinical management in 
a significant number of adults suffering from liver disease of unknown cause, 
gaining insight into disease pathogenesis and identifying new therapeutic and 
preventive medicine interventions. This study supports the use of WES in the 
evaluation and management of adults with idiopathic liver disease in clinical 
practice.  
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INTRODUCTION 
Liver Disease of Unknown Etiology: A Historical Perspective 
Liver disease is a major public health problem that affects approximately 30 
million people and leads to over 40,000 deaths annually in the United States.1 
Chronic liver disease (CLD) is often silent unless there is awareness of subtle 
clinical signs, behavioral risk factors and/or investigation of abnormal liver 
function tests. Untreated liver disease may progress to end-stage liver disease 
(cirrhosis) and further decompensation with ascites, hepatic encephalopathy, 
esophageal variceal hemorrhage, jaundice, and/or hepatocellular carcinoma, 
leading to liver failure and death.2 Advances in our understanding of liver disease 
have led to a marked decline in the attribution of CLD to “unknown etiology” 
(Figure 1). Prior to 1965, cryptogenic cirrhosis, defined as cirrhosis of unknown 
etiology after extensive clinical, laboratory, and histological analysis, accounted 
for >50% of all cases of cirrhosis.3 The discovery of hepatitis B virus (1965)4, 
hepatitis D virus (1977)5, and hepatitis C virus (1989)6 eventually led to the 
recognition of their contributions to cirrhosis worldwide. The description of non-
alcoholic steatohepatitis as a clinical entity in 19807, and improved diagnostic 
criteria for autoimmune hepatitis, first published in 19988, further reduced the 
diagnosis of cryptogenic cirrhosis, as did improved diagnosis of iron overload 
syndromes (i.e. HFE mutation)9, alpha-1-antitrypsin deficiency (A1ATD)10, and 
Wilson’s disease11 (Figure 1). However, it is currently estimated that up to 30% of 
cases of cirrhosis and up to 14% of adults awaiting liver transplantation suffer 
from liver disease of unknown etiology.12,13 In tertiary medical centers, the 
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incidence of cirrhosis of unknown etiology has been estimated at 5-10%.14 These 
patients often undergo a long and costly odyssey of diagnostic tests, 
interventions and medical opinions, and represent an understudied and 
underserved population. Understanding the etiology of CLD is essential to halt 
the progression of liver dysfunction, as illustrated by the development of a 
vaccine and anti-viral therapy for hepatitis B, and the highly effective, safe and 
curative anti-viral therapies for hepatitis C.15  
 
 
Figure 1: The incidence of cryptogenic cirrhosis has been steadily declining as new etiologies are 
being recognized, as outlined above. A1ATD, alpha-1-antitrypsin deficiency; HBV, hepatitis B 
virus; PFIC, progressive familial intrahepatic cholestasis (Byler disease); NASH, non-alcoholic 
steatohepatitis; HCV, hepatitis C virus; HFE, human hemochromatosis protein; AIH, autoimmune 
hepatitis; WES, whole-exome sequencing.   
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Current State of Genetic Analysis in Hepatology Clinical Practice 
The taxonomy of CLD in clinical practice is based broadly on categories of 
etiology such as exposure to toxins, viral infections, cholestatic, autoimmune, 
metabolic and select genetic disorders. A significant limitation of this approach is 
that it precludes consideration of a wider array of underlying genetic disorders 
masquerading within these broad phenotypes. Indeed, the current state of 
genetic analysis of adult liver disease in practice only involves the exclusion of a 
limited number of inherited conditions through single gene tests, including 
Wilson’s Disease (ATP7B), Hemochromatosis (HFE, HJV, HAMP, TFR2, 
SCL40A1), and A1ATD (SERPINA1). In some circumstances, commercial gene 
panel tests including the Jaundice Chip or EGL Cholestasis Panel are used, 
which include up to 72 genes.16 However, these panel tests represent only a 
small fraction of the ~20,000 protein coding genes of the human genome 
reference sequence, completed in 2003.17  
Whole-Exome Sequencing 
Advances in human genetics and genomics have created an unprecedented 
opportunity for gene discovery and diagnosis in the clinic. Over the past 15 
years, next-generation sequencing technologies have matured into an 
inexpensive, effective and widely available set of tools. One of these 
technologies, whole-exome sequencing (WES), consists of targeted capture and 
sequencing of the ~20,000 human protein-coding genes (Figure 2). Although 
WES excludes the 99% of the genome that does not code for proteins, it is 
estimated that approximately 85% of all mutations with large effects on disease-
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related traits are located within exomes.18 Furthermore, WES has traditionally 
been described as having excellent sensitivity and specificity (~98-99%), 
especially when the mean per-base coverage is over 20x and with a minimal 
local read depth of 13x.19 Importantly, various bioinformatics programs have 
been optimized to translate raw WES data into manageable and intelligible 
datasets: performing base calling (translating the raw signals from the 
sequencers into A, C, T or G, with an accompanying quality score), alignment of 
the reads to the human reference genome (searching for the best matching 
segment), removal of PCR duplicates (generated during preparation of the 
genomic library), variant calling (recording all positions that differ from the 
reference genome), and variant annotation (using data from various public 
databases such as ClinVar, Online Mendelian Inheritance in Man [OMIM], Exome 
Aggregation Consortium database [ExAC], gnomAD, 1000 Genomes, National 
Heart, Lung and Blood Institute’s [NHLBI] Exome Variant Server, HapMap, and 
others to provide information about minor allele frequency, function of the gene, 
degree of inter-species amino acid conservation, etc). Furthermore, there are 
existing computational tools for in silico assessment of a given variant’s 
pathogenic potential. As such, WES currently represents a remarkable balance 
between cost (<$300 for a research exome without analysis, ~$3000 for a clinical 
exome), time of analysis, and information collected, making it attractive and 
suitable for clinical use and translational research studies. Nearly 3,000 genes 
underlying over 4,000 Mendelian phenotypes have been discovered, and next-
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generation sequencing approaches including WES account for more than three 
times as many discoveries as conventional methods.20  
 
 
 
Figure 2: Overview of whole-exome sequencing pipeline. SNV, single nucleotide variant; Indel, 
insertion/deletion. Oligonucleotide probes designed to specifically hybridize to all exons in the 
genome are in solution. The probes are linked to magnetic beads. Other exome capture systems 
have probes attached to a microarray. Adapted from Gerald Goh and Murim Choi.21 
 
 
Diagnostic Utility of Whole-Exome Sequencing 
WES combined with deep clinical phenotyping has been increasingly applied as 
a first-line diagnostic tool in clinical medicine, particularly for the diagnosis of 
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inborn metabolic and neurodevelopmental disorders, unexplained liver failure in 
children22-26, as well as for the detection of causal mutations in cancer27,28. In 
these contexts, exome sequencing can inform medical management, including 
prognosis, choice of therapy, and accurate reproductive counselling. However, to 
date, most studies that investigate the use of next generation sequencing 
technologies in the diagnosis and individualization of medical care have been 
performed in either pediatric or cancer patients. There is a paucity of information 
on the clinical utility of these approaches for a broader spectrum of diseases 
among adults. A number of small studies and one study in a large cohort support 
the usefulness of exome sequencing for the diagnosis of early onset or familial 
nephropathy29-31, sporadic chronic kidney disease32, and inherited cardiovascular 
diseases33, however to date the utility of this approach in chronic liver disease 
has not been elucidated. By using unbiased genomic analysis, we may begin to 
understand parameters of adult clinical presentations that harbor an underlying 
monogenic cause, and to develop a more comprehensive category of ‘genetic’ 
liver diseases in adults beyond the traditionally considered disorders such as 
Wilson’s disease, A1ATD, or hemochromatosis. Here, we provide data to support 
the utility of WES in the diagnosis and management of adults with liver disease of 
unknown cause, with or without involvement of other diseases and/or unusual 
clinical findings. We also extend our analysis to an independent cohort of 
patients with fatty liver and physical exam findings suggestive of lipodystrophy, a 
group of heterogeneous disorders characterized by the absence or reduction of 
subcutaneous adipose tissue.   
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STATEMENT OF PURPOSE 
To assess the utility of whole-exome sequencing in the diagnosis and 
management of adults with unexplained liver disease. 
 
MAIN OUTCOMES AND MEASURES 
To obtain the diagnostic yield of WES and its direct impact in providing new 
therapeutic options, targeted preventive medicine interventions, and adequate 
family counselling.  
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PATIENTS AND METHODS 
Human Subjects 
Study protocol was approved by the Yale Human Investigational Committee, and 
informed consent was obtained in accordance with institutional review board 
standards. In cohort 1, nineteen adults with unexplained liver disease despite a 
comprehensive evaluation at Yale New Haven Hospital (unrevealing hepatitis 
viral serologies including negative HBsAg and anti-HBc, ferritin, iron studies, 
ceruloplasmin, ANA, alpha-1-antitrypsin phenotype, abdominal imaging, liver 
biopsy, etc) underwent further investigation using whole-exome sequencing. 
Patients may have had other medical co-morbidities but did not have a history of 
alcohol overuse. For some patients in the cohort, we questioned prior diagnosis 
such as non-alcoholic fatty liver disease (NAFLD) in absence of typical metabolic 
or body habitus features. Where possible, samples from available family 
members were also obtained for segregation studies. In cohort 2, we recruited 
four unrelated adult patients with fatty liver disease, insulin resistance/diabetes, 
hypertriglyceridemia, and physical exam findings suggestive of lipodystrophy per 
evaluation by an endocrinologist at Bridgeport Hospital. 
DNA isolation, exome capture and sequencing 
Genomic DNA was isolated from peripheral blood mononuclear cells or buccal 
swabs using standard procedures. DNA fragments contained in exonic sequences 
were captured and sequenced on the Illumina HiSeq platform.  
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Exome Sequencing Analysis 
Exome sequencing data were mapped and aligned to the reference human 
genome (reference sequence hg19) using BWA. Variants were called using 
GATK34,35 and annotated using Annovar.36 Since the goal of this project was to 
identify genetic causes for rare Mendelian conditions, we focused on variants 
that are uncommon in the general population. In other words, the higher the 
frequency of the variant, the lower the probability to be causal of a rare disease. 
Variants were selected for minor allele frequency (MAF) <0.01 for homozygous 
and compound heterozygous variants (recessive inheritance pattern) or <2x10-5 
for heterozygous variants (dominant inheritance pattern). Variants with MAF >1% 
are unlikely to cause recessive disorders with full penetrance (prevalence 
1:10,000 or less) in the general population. If autosomal dominance is the 
suspected pattern of inheritance, the favored MAF cutoff is more stringent 
because a single allele is sufficient to cause disease. Allele frequencies were 
determined using the genome aggregation database (gnomAD) databases,37 
including the Exome Aggregation Consortium database (ExAC), 1000 Genomes, 
and the National Heart, Lung and Blood Institute’s (NHLBI) Exome Variant 
Server. After filtering out common variants, variants located in intronic and 
intergenic segments of the genome were removed. Subsequently, protein-
altering variants were selected and prioritized based on their predicted 
deleteriousness. Deleterious prediction methods might filter, for example, coding 
variants that do not result in an amino acid change, substitutions that do not alter 
the physicochemical properties of protein product despite the mutated amino 
12 
 
 
acid, or amino acid variants that are not well conserved across orthologues. 
MetaSVM38 was used to infer the impact of missense mutations. Rare protein-
altering variants predicted to be deleterious were then selected if they occurred 
as pathogenic variants described in NCBI Clin Var, and/or in genes previously 
associated with liver-related diseases listed in the Online Mendelian Inheritance 
in Man (OMIM) database. BLAT, a local alignment software embedded within the 
UCSC Human Genome Browser39, was used to verify that a pathogenic variant 
and its surrounding sequences mapped specifically to the target gene. Figure 3 
outlines the genetic variant filtering strategy used in this study.  
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Figure 3. Representative flowchart of genetic variant filtering strategy in this study. Minor allele 
frequencies were determined using the gnomAD database. 
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Principal Component Analysis 
Principal component analysis (PCA) was performed to determine the ancestry of 
the patients in our cohort. All tag SNP genotypes (genotype of a subset of single 
nucleotide polymorphisms within a linkage disequilibrium block) were obtained 
from WES data and used as inputs, along with the same SNPs from subjects in 
the HapMap project, to perform PCA with EIGENSTRAT software.40  
Sanger Sequencing 
Sanger sequencing of the identified PPARG variant (p.Gly161Val) in patient 1 
was performed by PCR amplification of genomic DNA of the proband and her 
parents. Sanger sequencing of the identified ABCB4 variants (p.Arg549Cys and 
p.Ala934Thr) in patient 2 was performed by PCR amplification of genomic DNA 
of the proband, her mother and her son. Sanger sequencing of the identified 
ABCB4 variant (p.Ter1280Arg) in patient 3 was performed by PCR amplification 
of genomic DNA of the proband. Sanger sequencing of the identified NDFUB3 
variant (p.Trp22Arg) in patient 4 was performed by PCR amplification of genomic 
DNA of the proband and her parents. Sanger sequencing of the heterozygous 
splice-site variant (c.2067+1G>A) in APOB in patient 5 was confirmed by PCR 
amplification of genomic DNA of the proband. Forward and reverse primers for 
each variant are described in Table 1. 
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Table 1. Gene name, accession number, and forward and reverse primer sequences used for 
Sanger sequencing. 
 
Gene 
Symbol 
NCBI 
reference 
sequence 
 
Amino acid 
change 
Forward Primer Reverse Primer 
 
PPARG 
 
NM_015869 
 
p.Gly161Val 
 
5’-
CAGGCCAGTATACC
TTTCGC-3’ 
 
5’-
GGATCCGACAGTT
AAGATCACA-3’ 
 
ABCB4 NM_000443 p.Gly161Val 5’-
ATGTGGTGGTCCTT
CAGCTT-3’ 
5’-
CTTCAAGAGCTGAT
CCATGTTTTCT-3’ 
 
ABCB4 NM_000443 p.Ala934Thr 5’-
ACCAAATCGAAAAC
AACCGGCA-3’ 
5’-
AGGAGGCTGAAGA
GATGGTTACA-3’ 
 
ABCB4 NM_000443 p.Ter1280Arg 5’-
ATCAAGACAGGTGT
CACTTCTAACT -3’ 
5’- 
GAATGGGAGAGTC
AAGGAGCAT -3’ 
 
NDFUB3 NM_002491 p.Trp22Arg 5’-
GTGTTAATCTTTTCC
TTACAGACATGG-3’ 
5’-
CATTGAAAAGCAAC
ATAGACACTTG-3’ 
 
APOB NM_000384 c.2067+1G>A 5’- 
GGAAGTGCCTGGTG
GTTCTT-3’ 
5’- 
TTCCATCACTTGAC
CCAGCC-3’ 
 
 
  
16 
 
 
Orthologues 
Full-length orthologous protein sequences from both vertebrate and invertebrates 
were obtained from GenBank. Protein sequences were aligned using the 
ClustaW or Clustal Omega algorithm.  
Author Contributions 
A.D., E.O., D.A., M.S., J.B., D.J., P.K.M., and S.V. participated in patient 
recruitment and/or patient’s ascertainment and management; A.H. performed the 
exome sequencing analysis for all patients in the study; D.D., K.D., and A.B. 
assisted with DNA extraction, next-generation and Sanger sequencing analysis; 
X.Z., and D.J. analyzed pathologic specimens. A.H. wrote the thesis.  
17 
 
 
RESULTS 
Study population characteristics and whole-exome sequencing in cohort 1 
Nineteen adults with unexplained liver disease and no history of alcohol overuse 
were recruited from Yale New Haven Health after an unrevealing conventional 
work-up performed by a hepatologist. These individuals presented between the 
ages of 22 and 73 years-old with a variety of liver disorders (Table 2) with or 
without other co-morbidities. We performed individual whole-exome sequencing 
of germ line DNA isolated from each patient. Targeted bases were sequenced by 
a mean of 90 reads, with 94% of targeted bases having more than eight 
independent reads, and 92% having more than fifteen independent reads, 
conferring high confidence calling of homozygous and heterozygous variants 
across the exome (Table 3). Genomic analysis identified a monogenic disorder in 
five patients of this adult population cohort (~25%), gaining insight into liver 
disease pathogenesis and with direct impact on clinical management (Table 4). 
Ethnicity was determined using Principal Component Analysis (Figure 4).  
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Table 2: Summary of study population characteristics and demographics in cohort 1 (n = 19). n, 
number; HELLP, hemolysis, elevated liver enzymes and low platelet counts; yo, years-old. 
 
 
Clinical Category 
 
Patients, 
n 
Mean age 
(range), 
yo 
Male, 
n  
Female, 
n 
Alive 
n 
 
Deceased or 
transplanted 
n 
 
Cryptogenic cirrhosis 
 
7 
 
39 
(29-70) 
 
3 4 5 2 
 
Non-obese NAFLD +/- 
NASH 
 
6 
 
30 
(24-34) 
 
4 2 6 0 
 
Idiopathic cholestasis 
 
4 
 
46 
(23-73) 
 
3 1 3 1 
 
HELLP and severe 
hyperammonemia 
 
1 22 0 1 1 0 
 
Idiopathic noncirrhotic 
portal hypertension 
 
1 60 1 0 1 0 
Total 19 
 
38  
(22-73) 
 
11 8 16 3 
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Table 3: Sequencing coverage and quality metrics for patient cohort 1 (n = 19). 
 
Metric                   Value 
 
Read length, bp 
 
     74-99     
 
Mean independent reads per targeted base                       90 
  
% of targeted bases with ≥ 8 independent reads                       94.0 
 
Mean error rate 
 
 
                      0.0027 
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Table 4: Demographics, clinical features, and genetic diagnosis identified in five subjects in 
cohort 1, and its clinical implications. Ethnicity was determined by principal component analysis 
as described in Methods section; yo, years-old, F, female; M, male. 
 
 
Patient 
ID 
Age 
(yo) 
Ethnicity Sex Presenting Features 
 
Genetic Diagnosis  
 
Clinical 
Implications  
1 33 European F 
Lean NASH, 
hypertriglyceridemia, 
recurrent 
pancreatitis 
Familial Partial 
Lipodystrophy  
Type 3  
Initiation of leptin 
therapy; 
preventative 
cardiovascular 
measures; family 
counseling 
2 32 African F 
 
Cryptogenic 
cirrhosis 
decompensated by 
esophageal variceal 
hemorrhage 
 
MDR3 Deficiency  
Family 
counseling; 
transplant 
candidacy 
 
3 
 
29 European M 
 
Cryptogenic 
cirrhosis at 8 years-
old, now status post 
liver transplantation 
 
MDR3 Deficiency 
Family 
counseling; re-
transplant 
candidacy 
 
4 
 
 
32 
 
 
European 
 
 
M 
 
 
Non-obese NAFLD, 
recurrent avascular 
necrosis, short 
stature 
 
Mitochondrial 
complex I deficiency 
 
 
Supplementation 
with co-enzyme 
Q10, vitamins B2 & 
B5; preventive 
interventions;  
family counseling 
 
5 
 
24 
 
Asian 
 
M 
 
Lean NAFLD 
 
Heterozygous 
Familial Hypobeta-
lipoproteinemia  
 
 
Family 
counseling; 
consideration for 
vitamin E 
supplementation 
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Figure 4: Example of principal component analysis to determine ethnicity clustering. Tag SNPs 
from exome sequences of subjects in our cohort were combined with HapMAP SNP data and 
PCA was performed as described in Methods. This figure shows that the patient (red cross) 
strongly clusters with individuals of European ancestry.  
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Exome sequencing yields a diagnosis and initiation of therapy in a patient who 
suffered from devastating complications of undiagnosed Familial Partial 
Lipodystrophy Type 3 for 18 years 
Patient 1 is a 33 year-old female with biopsy proven severe (80-90%) hepatic 
macrovesicular steatosis with periportal and pericentral fibrosis (Figure 5A, B). 
There was moderate portal inflammation with occasional hepatocyte ballooning, 
rare poorly-formed Mallory-Denk bodies, ceroid laden macrophages and marked 
Kupffer cell siderosis. Her past medical history is significant for early onset 
hyperlipidemia diagnosed in childhood, recurrent episodes of 
hypertriglyceridemia-induced pancreatitis complicated by total pancreatectomy, 
splenectomy and insulin dependence. She also has history of hypertension and 
of pre-eclampsia at the age of 29. Her social and family history is non-
contributory. She had been seen and evaluated by many expert pediatric and 
adult physicians at several U.S. tertiary medical centers within the last 18 years 
and despite a comprehensive work-up, her operational diagnosis was 
hyperchylomicronemia syndrome although genetic deficiency of lipoprotein lipase 
or apolipoprotein CII could not be demonstrated.  
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Figure 5: Liver histology findings in patient 1, cohort 1. (A) Liver parenchyma shows marked 
steatosis with moderate steatohepatitis (H&E stain). (B) Trichrome stain of liver biopsy tissue 
shows portal, periportal and perisinusoidal fibrosis consistent with stage 2 fibrosis (Brunt grading 
and staging system).  
 
 
 
 
We performed WES of germ line DNA to investigate a possible underlying 
genetic defect. Since her biological parents were unaffected, we analyzed her 
exome data considering both a recessive as well as a dominant pattern of 
inheritance. Consistent with an unrelated union, no rare homozygous genotypes 
were observed in the proband. However, she harbored one missense variant 
(chr3:12434114, G>T, NM_015869, c.482G>T, p.Gly161Val) in PPARG (Figure 
6), which encodes peroxisome proliferator-activated receptor and heterozygous 
pathogenic variants in this gene have been related to autosomal dominant 
Familial Partial Lipodystrophy Type 3 (FPLD3). This variant is predicted to be 
damaging by MetaSVM and it is absent among > 100,000 alleles in the gnomAD 
database, and therefore is likely to be pathogenic in this patient (Table 5). 
Sanger sequencing confirmed the heterozygous variant in the proband and 
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further showed that neither parent harbors the variant, revealing that it occurred 
de novo in the patient (Figure 7A). This variant is located in the DNA binding 
domain of the PPARG protein at a highly conserved position across orthologues 
(Figure 7B). Moreover, a single case of an older female with clinical features 
consistent with FPLD3 and harboring the same PPARG variant (p.Gly161Val) as 
patient 1 has been reported.41 At this point, in light of new genotype knowledge 
and presumed diagnosis, we re-evaluated her clinical and laboratory findings, 
which were consistent with FPLD3. 
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Figure 6: Representative plot read of disease-causing mutation identified in Patient 1, cohort 1, 
identified using next generation sequencing. This illustrates the concept of reads and coverage for 
a particular genomic segment.  
  
PPARG, chr. 3:12434114, c.482G>T, p.Gly161Val 
 
Reference 
Genome 
A  
G  
T   
C 
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Table 5: Diagnostic genetic variants identified in five subjects in cohort 1. AA, amino acid; 
gnomAD, Genome Aggregation Database (includes 123,136 exome and 15,496 whole-genome 
sequences); MAF, minor allele frequency; MetaSVM scores missense variants on a scale of -2 to 
3, with scores <0 predicted to be tolerated (T) and scores >0 predicted to be damaging (D); yo, 
years-old; N/A, not applicable. 
 
 
Patient 
ID 
 
Gene 
 
 
 
Inheritance 
and Effect of 
Variant 
 
AA or cDNA 
change 
 
 
Meta SVM 
score 
prediction 
 
gnomAD 
(overall) 
 
 
gnomAD 
(highest 
frequency) 
 
1 
PPARG 
(NM_015869) 
Heterozygous, 
Missense 
p.Gly161Val 
(c.482G>T) 
1.104 (D) 0 0 
 
2 
 
 
 
ABCB4 
(NM_000443) 
 
 
 
Compound 
Heterozygous, 
Missense 
 
p.Arg549Cys 
(c.1645C>T) 
 
p.Ala934Thr 
(c.2800G>A) 
0.448 (D) 
 
 
 
0.676 (D) 
0 
 
 
 
1.3e-3 
 
0 
 
 
 
1.4e-2 
(African) 
 
3 
 
ABCB4 
(NM_000443) 
Homozygous, 
Stop loss 
p.Ter1280Arg 
(c.3838T>A) 
N/A 0 0 
 
4 
 
NDUFB3 
(NM_002491) 
Homozygous, 
Missense 
p.Trp22Arg 
(c.64T>C) 
0.485 (D) 8.2e-4 
 
1.3e-3 
(European) 
 
 
5 
 
 
 
APOB 
(NM_000384) 
 
Heterozygous, 
Splice Site 
c.2067+1G>A N/A 0 0 
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Figure 7: Genetic findings in patient 1, cohort 1. (A) Pedigree depicts proband and unaffected 
subjects in black and white symbols, respectively, with Sanger sequencing chromatograms of the 
proband and her unaffected parents. PPARG alleles are denoted WT (wild-type) or Mut 
(p.Gly161Val). The PPARG p.Gly161Val variant is heterozygous in the proband and absent in 
both parents. (B) Location of Gly-161 in PPARG and its conservation across species. The 
patient’s variant is in a highly conserved DNA-binding domain (DBD) of the PPARG protein. 
Amino acid positions identical to the human reference are highlighted in yellow. N-terminal 
transactivation domain (AF1), highly conserved DNA-binding domain (DBD), C-terminal ligand-
binding domain (LBD).  
 
 
 
 
PPARG is known to be a key transcription factor in adipocyte differentiation, 
which explains the lack of adipose tissue in the patient and the striking 
accumulation of triglycerides in the bloodstream as well as its accumulation in 
other organs, such as the liver (Figure 8). Given the diagnosis of FPLD3 and 
physical exam findings of decreased overall adiposity, we postulated that the 
patient’s leptin levels should be low since leptin is mainly produced by 
adipocytes. As predicted, her leptin level was significantly low at 1.5 ng/mL 
(normal range for age and gender = 8.0-38.9 ng/mL) (Figure 9A). This finding not 
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only supported our genetic diagnosis, but led to a new therapeutic intervention. 
The patient was initiated on leptin replacement therapy in a compassionate use 
program. During the ensuing 13 months there was significant amelioration of 
dyslipidemia: total cholesterol fell from 238 to 130 mg/dL, triglyceride levels fell 
from 3532 to 267 mg/dL, and HDL cholesterol increased from 8 to 24 mg/dL 
(Figure 9A). Concomitantly, there was normalization of her liver transaminases: 
AST and ALT levels decreased from 114 to 19 U/L and from 94 to 17U/L, 
respectively (Figure 9B). Furthermore, the patient’s daily insulin requirements 
decreased by approximately half compared to doses of insulin required prior to 
leptin replacement therapy.  
 
 
 
 
 
Figure 8: Illustrative representation of the role of PPARG, peroxisome proliferator-activated 
receptor-gamma, in adipocyte differentiation and relationship to serum leptin. Adapted from 
Tsoukas and Mantzoros.42 
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Figure 9: Laboratory findings in patient 1, cohort 1. (A) Triglycerides and leptin levels before (no 
shadow) and after (depicted by a gray shadow) initiation of leptin replacement therapy. (B) 
ALT/AST levels before (no shadow) and after (depicted by a gray shadow) initiation of leptin 
replacement therapy. LLN, lower limit of normal; ULN, upper limit of normal. 
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MDR3 deficiency diagnosed in adulthood in two unrelated patients 
Patient 2 is a 31-year-old female who presented with an acute esophageal 
variceal hemorrhage in her 22nd week of her second gestation. Of note, the 
patient had symptomatic cholestasis during her first pregnancy and she was 
diagnosed with benign intrahepatic cholestasis of pregnancy at that time. On this 
presentation, she had severe cholestasis (with high -glutamyltransferase, GGT) 
and liver biopsy revealed cirrhosis and cholestasis with ductular proliferation 
(Figure 10A, B). WES revealed two rare variants predicted to be damaging by 
MetaSVM (chr7:87069069, C>T, NM_000443, c.1645C>T, p.Arg549Cys and 
chr7:87041333, G>A, NM_000443, c.2800G>A, p.Ala934Thr) in ABCB4, which 
encodes ATP binding cassette subfamily B member 4, also known as multiple 
drug resistance protein 3 (MDR3) (Table 5). There were no other disease-
causing variants in genes known to be associated with liver disease, using 
recessive or dominant models. Sanger sequencing confirmed both variants in the 
patient’s genomic DNA. Study of available family members revealed that her 
mother is a heterozygous carrier of p.Arg549Cys whereas her son is 
heterozygous for the other variant, p.Ala934Thr, supporting that the two variants 
found in our patient were located in trans at the ABCB4 gene locus (Figure 11A, 
B), consistent with an autosomal recessive disorder. Both variants are conserved 
across orthologues (Figure 12). As expected, her total bile acids (cholic acid, 
deoxycholic acid and chenodeoxycholic acid) levels have been persistently 
elevated, ranging from 36 to 105mol/L (normal is <6.8mol/L).  
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Figure 10: Liver histology findings in patient 2, cohort 1. (A) Trichrome stain for patient 2 reveals 
fibrous septa with nodule formation consistent with cirrhosis. (B) Cytokeratin 7 
immunohistochemical staining (depicted in brown) for patient 2 shows ductular proliferation.  
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Figure 11: Genetic findings in patient 2, cohort 1. (A) Pedigree depicts patient 2 and unaffected 
subjects shown in black and white symbols, respectively. (B) Sanger sequencing chromatograms 
of the proband (patient 2) and her unaffected mother and son. The patient harbors two variants in 
ABCB4, p.Arg549Cys and p.Ala934Thr, whereas her mother and her son solely carry one of 
these variants each, p.Arg549Cys and p.Ala934Thr, respectively.  
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Figure 12: Conservation findings in patient 2, cohort 1. Conservation of Arg-549 and Ala-934 
across species, respectively. Amino acid positions identical to the human reference are 
highlighted in yellow.  
 
 
Patient 3 is a 29 year-old male with past medical history significant for liver 
transplantation at 8 years of age for cirrhosis of unclear etiology who presented 
with chronic graft rejection in the setting of medical non-adherence. Consistent 
with known consanguinity, patient 3 harbors twenty-seven rare homozygous 
variants. Twenty-six of these variants are missense variants in genes unrelated 
to liver disease by OMIM, and therefore are unlikely to be causal pathogenic 
variants in this patient. The other homozygous variant encoded a stop lost in 
ABCB4 (chr7:87031414, T>A, NM_000443, c.3838T>A, p.Ter1280Arg), which 
was confirmed by Sanger sequencing (data not shown). This variant has never 
been reported in general population by gnomAD. However, another substitution 
in the same nucleotide (NM_000443 c.3838T>C) resulting in an identical stop-
loss variant in the p.Ter1280 codon has been previously associated  with 
cholestasis and liver failure.43 Both the c.3838T>A and c.3838T>C nucleotide 
substitutions result in extension of the protein by 19 new amino acids. Given new 
knowledge of the patient’s genotype, we reviewed the patient’s liver explant. 
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Liver parenchyma showed cirrhosis with patchy macrovesicular steatosis, 
portal/septal chronic inflammation, marked cholestasis with ductular proliferation 
and increased hepatocytic copper deposition (Figure 13A, B, C, D), consistent 
with a genetic diagnosis of MDR3 deficiency. 
 
 
 
 
 
 
Figure 13: Liver histology findings in patient 3, cohort 1. (A) Liver parenchyma (H&E stain) from 
patient 3 showing cirrhosis. (B, C) Liver parenchyma (H&E stain) from patient 3 at lower and 
higher magnification, respectively, revealing portal/septal chronic inflammation, ductular 
proliferation, and marked cholestasis. (D) Copper stain of liver parenchyma for patient 3 
supporting marked cholestasis. 
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Recessive variant in NDFUB3 in a patient with elevated transaminases, hepatic 
steatosis, recurrent avascular necrosis and short stature 
Patient 4 is a 32 year-old male with persistent elevation of transaminases (AST 
and ALT ~3 times upper limit of normal), recurrent avascular necrosis, and short 
stature (with both parents of average height). Liver biopsy showed minimal 
macrovesicular (small and large droplet fat) steatosis (<5%) (Figure 14A, B). He 
is the single child of unrelated European-descended parents. WES was 
remarkable for a very rare homozygous variant in NDUFB3 (chr2:201943669, 
T>C, NM_002491, c.64T>C, p.Trp22Arg), which encodes for NADH-
dehydrogenase 1 beta complex 3 and consists of the first enzyme in the electron 
transport chain in mitochondria (Table 5). Both parents were found to be 
heterozygous for this variant by Sanger sequencing (data not shown). This 
variant is predicted to be damaging by MetaSVM and it was first reported in a 
single female infant with lethal complex I mitochondrial deficiency44 and more 
recently in 10 children from 8 families, seven of them of Irish ancestry.45 In this 
last cohort, all patients have short stature (<9th percentile) and similar facial 
dysmorphic features to patient 4, such as a prominent forehead, smooth philtrum 
and deep-set eyes. In contrast to the first patient reported with this homozygous 
variant, they have a good long-term prognosis, even though some patients 
presented with an acute metabolic crisis with evidence of an isolated complex I 
deficiency in muscle.45 In light of new genotype information, our patient 4 had 
mitochondrial ETC testing in skeletal muscle biopsy that revealed a deficiency of 
rotenone sensitive I+III activity despite normal citrate synthase activity, which 
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fulfills a minor criterion of the modified Walker criteria for diagnosis of a 
respiratory chain disorder (<30%). Liver electron microscopic findings were also 
suggestive of a mitochondrial abnormality, with hepatocytes showing different 
sized lipid droplets (Figure 14C). Moreover, the patient suffers from oculomotor 
dysfunction with optic nerve anomalies, episodes of lactic acidosis during 
surgical interventions, and progressive fatigue. He was started on mitochondrial 
cocktail supplement, including co-enzyme Q10, vitamins B2 and B6.  
 
 
 
Figure 14. Liver biopsies of patient 4, cohort 1. (A, B) Patient 4 liver parenchyma shows near normal 
histology with minimal macrovesicular steatosis (small and large droplet fat) (H&E stain) at lower 
and higher magnification, respectively. (C) Electron microscopic findings for patient 4 are 
suggestive of a mitochondrial abnormality, with hepatocytes showing different sized lipid droplets.  
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Lean patient with hepatic steatosis of unknown etiology was found to have a novel 
damaging heterozygous variant in APOB 
Patient 5 is a 23 year-old lean male who presented for evaluation of persistent 
elevated ALT (2 to 3 times upper limit of normal) for which he underwent a liver 
biopsy that showed mild macrovesicular steatosis (30%) with minimal lobular 
inflammation and minimal pericentral sinusoidal fibrosis (Figure 15). His work-up 
was also remarkable for a ceruloplasmin of 17mg/dL (normal range =18-
36mg/dL). WES analysis revealed no rare variations in ATP7B and a pathogenic 
heterozygous splicing variant in APOB (chr2:21250699, c.2067+1G>A), which 
encodes apolipoprotein B (ApoB). This change was validated by Sanger 
sequencing (data not shown) and is predicted to abrogate the normal splicing of 
exon 14 in the APOB gene. Heterozygous carriers typically have decreased 
plasma levels of LDL-cholesterol and ApoB, and may be asymptomatic or have 
clinical manifestations such as liver steatosis.46,47 Consistent with the patient’s 
genotype, his circulating ApoB level was found to be half the lower limit of normal 
(26 mg/dL compared to normal range of 52 to 109 mg/dL), with low circulating 
LDL cholesterol (20mg/dL) and triglyceride (19 mg/dL) levels. Thus, this new 
genotype information explains both clinical and laboratory findings in this patient, 
and may have implications in his clinical management beyond family counseling. 
Specifically, fat-soluble vitamin E supplementation has been recommended for 
patients with homozygous hypobetalipoproteinemia to protect from neurological 
complications, and modest doses of Vitamin E have been proposed for treatment 
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of heterozygous patients,48 but further studies are required. Vitamin E has also 
been shown to be beneficial in those with non-alcoholic steatohepatitis.49  
 
 
 
 
Figure 15. Liver biopsy of patient 5, cohort 1. Hepatic parenchyma (H&E stain) from patient 5 
shows predominantly macrovesicular steatosis with minimal steatohepatitis. 
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Outcomes of patients for patients in cohort 1 who remain unexplained after whole 
exome sequencing analysis 
Fourteen patients in cohort 1 remain unexplained after genomic analysis. Our 
study aimed to demonstrate the utility of unbiased WES in attaining a definitive 
diagnosis in adults with idiopathic liver disease. Therefore, we utilized a 
conservative approach (to avoid false positives), and focused our analysis on 
variants previously reported as pathogenic in Clin Var and/or in genes associated 
with liver-related phenotypes by OMIM. Our study was not designed or powered 
to identify novel liver disease genes, to determine phenotypic impact of variants 
predicted to be benign by in silico methods (which would require dedicated 
functional analysis) or to search for disease-causing mutations with minor allele 
frequency above the thresholds discussed above.  
Each of the 14 patients that remain undiagnosed in our cohort harbor rare 
variants in (1) genes not known to be related to liver disease and/or (2) in genes 
related to liver disease, but which do not fulfill the known genetic model of 
inheritance (i.e. patient harbors one heterozygous variant in a liver disease-
related gene that is known to cause a recessive disorder where both alleles need 
to be mutated to cause disease, such as ATP7B) or are not supported by 
phenotype (a genetic diagnosis alone cannot establish the clinical diagnosis if not 
in accordance with clinical findings and should be strictly used in conjunction with 
the clinical data). Table 6 summarizes the outcomes of the 14 patients that 
remained unexplained.  
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Table 6. Summary of outcomes for fourteen patients who remain unexplained after whole exome 
sequencing analysis. Table shows the number of genes with rare deleterious variants (includes 
premature termination, splice-site, frameshift and missense variants predicted to be deleterious 
by MetaSVM) and with benign variants (includes missense variants predicted to be tolerated by 
MetaSVM). All rare deleterious variants in these fourteen patients occur in (1) genes not known to 
be related to liver disease and/or (2) in genes related to liver disease, but which do not fulfill 
known genetic model of inheritance or are not supported by phenotype. Rare deleterious variants 
found in liver disease-related genes are indicated below. 
 
 
 
 
 
Patient ID 
 
Recessive Pattern of Inheritance 
 
 
Dominant Pattern of Inheritance 
 
Homozygous 
variants 
Two heterozygous 
variants in the same gene 
Heterozygous variants 
 Deleterious Benign Deleterious Benign Deleterious Benign 
6 0 1 0 3 12a 34 
7 0 2 0 7 15 50 
8 1 3 0 4 6b 19 
9 0 2 0 16 29 81 
10 0 5 0 8 18 56 
11 0 4 0 47 11 46 
12 0 1 0 14 18 51 
13 0 0 0 4 13 34 
14 0 0 0 8 9c 39 
15 0 3 1d 6 20 68 
16 0 5 0 0 12 42 
17 0 4 0 10 17 28 
18 0 0 0 4 8 27 
19 0 0 0 3 8 41 
 
aone heterozygous deleterious missense variation in ABCB4, chr7:87076396, NM_000443, 
c.959C>G, p.Ser320Cys. Laboratory tests and liver biopsy findings show no cholestasis.  
 
bone heterozygous deleterious missense mutation in SLC40A1, chr2:190426791, NM_014585, 
c.1529T>C, p.Met510Thr; the patient’s phenotype is not consistent with autosomal dominant 
hereditary hemochromatosis (normal ferritin and normal-to-low transferrin saturation). 
 
cone heterozygous splice site variation in ABCB4, chr7:87032450, NM_000443, c.3492+1G>A. 
The patient suffered from decompensated cirrhosis of unclear etiology with preserved bile ducts 
seen on biopsy, now status post liver transplantation. Additionally, at the time of transplant, the 
gallbladder showed no significant histopathologic abnormality.  
 
dtwo heterozygous frameshift mutations in ATP7B: chr13:52548577  NM_000053, c.778T>TG, 
p.Gln260fs and 13:52548830, NM_000053, c.524CTT>C, p.Lys175fs. Segregation studies 
revealed that patient’s unaffected mother also carries both variants and therefore they are in cis. 
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Patient 13 presented with cholestasis of unclear etiology. Whole exome 
sequencing revealed a rare, heterozygous deleterious mutation in peroxisome 
proliferator-activated receptor delta, or PPARD, 6:35393750, NM_001171820, 
c.926G->A, p.R309Q. PPARD is a nuclear receptor expressed in hepatocytes, 
cholangiocytes, Kuppfer cells and hepatic stellate cells, and it controls genes 
involved in bile acid homeostasis. Selective agonists of the PPARD receptor 
have been shown to be potent anti-cholestatic agents in clinical trials,50 however 
mutations in PPARD have not been previously associated with cholestatic liver 
diseases. The primary therapeutic effects of the PPARD selective agonists in 
patients with primary biliary cholangitis result from decreasing hepatocellular bile 
acid concentrations by downregulation of CYP7A1, which encodes cholesterol 7-
alpha-hydroxylase, the enzyme that hydroxylates cholesterol in the first step in 
the synthesis of bile acids.50,51 As a consequence, we hypothesized that patient 
13 may have had increased activity of cholesterol 7-alpha-hydroxylase, leading 
to idiopathic cholestasis. To assess this, we measured serum C4 concentrations 
(7-alpha-hydroxy-4-cholesten-3-one) in peripheral blood, a reliable marker of the 
activity of hepatic 7-alpha-hydroxylase.52 It is known that serum C4 concentration 
in non-cirrhotic and cirrhotic primary biliary cholangitis patients is normal or low 
compared to healthy control subjects.53 The patient’s bile acids were elevated 
(deoxycholic acid 4.5 µmol/L [normal <2.4 µmol/L], chenodeoxycholic acid 4.6 
µmol/L [normal <3.1 µmol/L], and total bile acids 10.8 µmol/L [normal <6.8 
µmol/L]), consistent with known cholestasis despite ongoing ursodiol therapy. 
However, the results of the serum C4 concentration were within normal limits at 
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2.7 ng/mL (normal range 2.5-63.2 ng/mL), suggesting that increased activity of 
liver cholesterol 7-alpha-hydroxylase was not contributing to the patient’s 
phenotype. Further studies on other cholesterol synthesis intermediates known to 
be regulated by PPARD (squalene, lanosterol, desmosterol, lanthosterol, and 7-
dehydrocholesterol), as well as intestinal cholesterol absorption markers known 
to be regulated by PPARD (β-sitosterol, campesterol, sigmasterol, coprostanol) 
are in progress.  
 
Study population characteristics and whole-exome sequencing in cohort 2 
Four adults were recruited from Bridgeport Hospital presenting with fatty liver 
disease, insulin resistance/diabetes, hypertriglyceridemia and physical exam 
findings suggestive of lipodystrophy per evaluation by an endocrinologist. 
Individual whole-exome sequencing of germline DNA isolated from each patient 
was performed. Targeted bases were sequenced by a mean of 75 reads, with 
94% of targeted bases having more than eight independent reads, and 93% 
having more than fifteen independent reads (Table 7). We identified a pathogenic 
genetic alteration that could potentially explain the phenotype in all four patients 
in this cohort, with possible clinical implications of the diagnosis in each case 
(Table 8). Two patients had genetic alterations in genes previously associated 
with lipodystrophy (LMNA and PPARG) and which are included in 
comprehensive lipodystrophy sequencing panels, however two patients had 
alterations in genes not routinely found on lipodystrophy panels (LEPR and 
APOE).  
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Table 7: Sequencing coverage and quality metrics for patient cohort 2 (n = 4)    
Metric                   Value 
 
Read length, bp 
 
                      99 
 
Mean independent reads per targeted base                       75 
  
% of targeted bases with ≥ 8 independent reads       94.3 
 
Mean error rate 
 
 
                      0.0024 
 
 
 
 
Table 8: Demographics, clinical features, and genetic diagnosis identified in four subjects in 
cohort 2, and its clinical implications. Ethnicity was determined by principal component analysis 
as described in Methods section; yo, years-old, F, female; M, male 
 
 
Patient 
ID 
Age 
(yo) 
Ethnicity Sex Presenting Features 
 
Genetic Diagnosis  
 
Clinical 
Implications  
1 62 European F 
Diabetes, hepatic 
steatosis  
Familial Partial 
Lipodystrophy  
Type 2 
Consideration for 
leptin therapy; 
preventative 
cardiovascular 
measures; family 
counseling 
2 46 Mexican F 
 
Cirrhosis with 
steatohepatitis 
 
Type 3 
hyperlipoproteinemia  
 
Preventative 
cardiovascular 
measures; family 
counseling  
 
 
3 
 
45 Mexican F 
 
Hypertriglyceridemic 
pancreatitis 
 
Leptin receptor 
deficiency 
 
Consideration for 
MCR4 agonist 
therapy, family 
counseling 
 
 
4 
 
 
32 
 
European 
 
F 
 
 
Hypertriglyceridemic 
pancreatitis, 
diabetes 
 
Familial Partial 
Lipodystrophy Type 
3 
 
Initiation of 
pioglitazone; 
preventative 
cardiovascular 
measures; family 
counseling  
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Genomic analysis in patients with fatty liver disease and lipodystrophy-like 
phenotype in cohort 2 
Patient 1 in cohort 2 presented with hepatic steatosis and insulin resistance and 
was found to harbor a heterozygous missense mutation in LMNA (p.Leu92Val), 
encoding lamin A/C. This led to the diagnosis of Type 2 familial partial 
lipodystrophy (FLPD2), also called Dunnigan disease, a rare autosomal dominant 
lipodystrophic disorder (Table 9). FPLD2 disease manifestations comprise 
subcutaneous fat loss in the buttocks, trunk and limbs, resulting in peripheral 
muscular hypertrophy and cervicofacial fat accumulation.54 Metabolic 
complications, resulting from an inability to properly store lipids, are very 
common and are usually revealed by hypertriglyceridemia and diabetes. Patients 
are also at risk for cardiomyopathy, arrhythmia, coronary artery disease, 
infertility, and eclampsia.54 Knowledge of genotype therefore informs preventive 
medicine, reproductive counselling, and the surveillance for early occurrence of 
metabolic complications in young generations. Moreover, two independent 
studies have evaluated leptin replacement therapy (n = 6 and n = 24) with the 
Dunnigan-type familial partial lipodystrophy, demonstrating efficacy in decreasing 
circulating triglycerides and liver steatosis.55  
Patient 2 in cohort 2 presented with cirrhosis and steatohepatitis and had 
elevated LDL-C (240 mg/dL), and triglycerides (496 mg/dL). She was found to be 
heterozygous for two rare point mutations in APOE (p.Glu31Lys and 
p.Arg163Cys), reported to be pathogenic by Clin Var. Both mutations have been 
previously reported in a 24-year-old Puerto Rican white female with severe type 
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3 hyperlipoproteinemia, who presented with palmar xanthomas and 
tuberoeruptive xanthomas on the elbows, knees, and buttocks, increased plasma 
cholesterol and triglyceride levels, and the presence of cholesterol and apoE-
enriched VLDL and chylomicron remnants.56 It is well documented that the 
absence of apolipoprotein E predisposes to hypercholesterolemia, 
atherosclerosis, and obesity.57 Furthermore, ApoE-/- mice fed a high-fat-diet 
mimic major characteristics of human NASH including steatosis, inflammation 
and fibrosis.58,59 Of note, mutations in apolipoprotein E have not been previously 
associated with the lipodystrophy phenotype.  
Patient 3 presented with abdominal pain and was diagnosed with 
hypertriglyceridemic pancreatitis (triglycerides of 2076 mg/dL). She had 
prominent central obesity with a paucity of adipose tissue on the extremities and 
gluteal region. Family history was significant for pancreatitis in the mother and 
maternal grandfather, and NASH in her 14-year-old son and sister. Whole exome 
sequencing uncovered a novel homozygous deleterious mutation in the leptin 
receptor (p.Ser389Asn). Congenital deficiency of the leptin receptor in humans 
results in extreme obesity and characteristic features of hyperphagia, obesity, 
hypogonadism, and impaired T-cell-mediated immunity.60 It is also associated 
with the selective deposition of fat mass, as seen in subjects with leptin 
deficiency. Interestingly, patient 3 appears to have a milder phenotype (BMI of 
27, mild hyperphagia, FSH, LH and TSH within normal limits) compared to 
previously described cases of congenital deficiency of the leptin receptor. 
Heterozygotes who are leptin receptor-deficient but not obese are known to have 
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increased fat mass.60,61 Further workup also showed low fasting leptin (4.2 
ng/mL, reference range 8.0-38.9 ng/mL). Ongoing work will elucidate the 
functional status of the mutated receptor in this patient using T-cells, which are 
known to express the leptin receptor. We will also screen family members and 
search for potential genetic modifiers of the LEPR-deficient state in this patient. 
Interestingly, MCR4 agonist therapy with setmelanotide has been suggested as a 
potential therapeutic option for severely obese patients with leptin receptor 
deficiency.62  
Patient 4 presented with hypertriglyceridemic pancreatitis (triglycerides of 4299 
mg/dL), and was found to have a previously described mutation in PPARG. The 
p.Arg194Trp mutation is at a position highly conserved across orthologues, 
leading to clinical manifestations of FPLD3 and associated metabolic 
disturbances.63 In vitro, this mutation was found to disrupt DNA binding activity 
and lead to haploinsufficiency, with no dominant negative activity. The patient 
was found to have a leptin level at the lower limit of normal and was started on 
pioglitazone, which selectively stimulates the nuclear receptor PPARG.  
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Table 9: Diagnostic genetic variants identified in cohort 2. *Pathogenic according to Clin Var. AA, 
amino acid; gnomAD, Genome Aggregation Database (includes 123,136 exome and 15,496 
whole-genome sequences); MAF, minor allele frequency; MetaSVM scores missense variants on 
a scale of -2 to 3, with scores <0 predicted to be tolerated (T) and scores >0 predicted to be 
damaging (D); yo, years-old; N/A, not applicable. 
 
 
Patient 
ID 
 
Gene 
 
 
 
Inheritance 
and Effect of 
Variant 
 
AA or cDNA 
change 
 
 
Meta SVM 
score 
prediction 
 
gnomAD 
(overall) 
 
 
gnomAD 
(highest 
frequency) 
 
1 
LMNA 
(NM_001282
626) 
Heterozygous, 
Missense 
p.Leu92Val 
(c.274C>G) 
 0.547 (D) 0 0 
 
2 
 
 
 
APOE 
(NM_000041) 
 
 
 
Compound 
Heterozygous, 
Missense 
 
p.Glu31Lys 
(c.91G>A) 
 
p.Arg163Cys 
(c.487C>T) 
-0.751 (T)* 
 
 
0.147 (D)* 
 
1.3e-4 
 
 
 
0 
3.4e-4 
(Latino) 
 
 
0 
 
3 
 
 
LEPR 
(NM_001198
687) 
 
Homozygous, 
Missense 
p.Ser389Asn 
(c.1166G>A) 
0.882 (D) 0 0 
 
4 
 
PPARG 
(NM_015869) 
Heterozygous, 
Missense 
p.Arg194Trp 
(c.580C>T) 
1.014 (D) 4.0e-6 
 
8.0e-6 
(European) 
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DISCUSSION 
This study provides evidence that a subset of adult patients who suffer from liver 
disease of indeterminate etiology with or without other co-morbidities harbors an 
underlying Mendelian disorder, which may be unrecognized during their entire 
childhood until genetic testing is performed. These findings have several 
implications. First, by establishing a diagnosis for a substantial number of 
undiagnosed cases, we provided new insights into disease pathogenesis. 
Second, knowledge of genotype led to recognition of unappreciated phenotypic 
features as well as new therapeutic and preventive medicine interventions 
beyond family counseling. For example, genomic analysis in patient 1 (cohort 1) 
led to recognition of phenotypic aspects unappreciated by standard clinical 
examination by specialists not familiar with the FPLD3 phenotype. It also led to 
initiation of leptin replacement therapy with striking amelioration of metabolic 
dysregulation and liver disease. Correct diagnosis additionally allowed 
appropriate attention to monitoring and prevention of premature coronary artery 
disease and other cardiovascular risk factors. Third, our data highlight the 
importance of using WES in the investigation of liver disease of unknown cause 
so that we may start developing an understanding of what clinical 
presentations/diseases are genetic and may remain undiagnosed until adulthood. 
The genetic diagnosis of MDR3 deficiency in patient 2 (cohort 1) underscores the 
silent progression of inherited chronic liver disease to cirrhosis, portal 
hypertension and decompensation, remaining unrecognized for decades and 
with first presentation in adulthood.64 Fourth, reminiscent of the widely accepted 
49 
 
 
Radiology and Pathology Rounds in clinical practice, this study illustrates the 
potential clinical value of Genome Rounds in the individual assessment and 
medical care of adults suffering from liver disease of unknown cause (Figure 16). 
This approach perfectly exemplifies the mission of the Precision Medicine 
Initiative65
 
launched by U.S. President Barack Obama in January 2015. 
Physicians recognize that every patient is unique and have always tried to adjust 
their interventions as best they can to each individual. Now, we have the 
technology and knowledge to start translating this concept to routine clinical 
practice in tertiary medical centers across the world. Even in the contemporary 
taxonomy of liver diseases, there is little understanding of the heterogeneity of 
disease within each category and distinct subtypes based on their underlying 
genetic mutations and/or pathobiology. This concept is illustrated by the three 
cases in cohort 1 (patients 1, 4 and 5) and four cases in cohort 2, who each 
harbor distinct genetic defects affecting different molecular pathways leading to 
hepatic steatosis and presumed diagnosis of NAFLD, with direct implications in 
bedside therapeutic and preventive medicine interventions.  
The four patients with metabolic abnormalities and physical exam findings of 
abnormal subcutaneous fat distribution in cohort 2 all harbored independent 
genetic alterations that may explain the phenotype. Interestingly, two of these 
patients harbored alterations in genes not included in lipodystrophy gene panels 
(LEPR and APOE), suggesting the utility of an unbiased genomic approach in 
cases of suspected lipodystrophy. Indeed, current guidelines recommend either 
“candidate gene sequencing, a panel of candidate genes, or whole-
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exome/whole-genome sequencing”.66 Due to the clinical similarities of 
lipodystrophy with the common obesity-related metabolic syndrome, we suspect 
that many such patients are overlooked. Careful physical examination of patients 
with insulin resistance and hypertriglyceridemia combined with WES could help 
identify lipodystrophy patients and lead to novel therapeutic strategies. We 
suspect that the higher diagnostic yield in this cohort is the result of a more 
targeted clinical phenotyping used for enrollment, although further study is 
required.  
Our study also provides support that a genomic approach to patients with 
undiagnosed liver diseases and/or unusual clinical presentations could lead to 
the discovery and development of new rational and targeted therapeutics. For 
example, loss of function mutations in PPARG and the concomitant phenotypic 
features of insulin resistance, hypertriglyceridemia, and fatty liver disease 
motivates the potential use of pharmacologic agonists to this nuclear receptor for 
the treatment of diabetes, hypertriglyceridemia, and NASH. Indeed, the 
thiazolidinediones, well-known PPARG agonists, are FDA-approved anti-diabetic 
agents, and recent randomized studies have shown utility for the treatment of 
NASH and dyslipidemia.49,67 Patient 5 in cohort 1 presented with hepatic 
steatosis and was found to have a mutation in APOB, leading to reduced LDL-C 
and apolipoprotein B levels. Notably, the FDA-approved drug mipomersen, an 
antisense oligonucleotide inhibitor of apolipoprotein B synthesis, has a black box 
warning for increasing hepatic steatosis, and elevated liver transaminases. 
Mipomersen reduced apolipoprotein B levels by ~22% and LDL-C by ~21% after 
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26 weeks, but also increased mean hepatic fat by ~10% and elevated liver 
transaminases to 2-3x ULN, thereby providing a pharmacologic correlate to the 
apo B phenotype.68 We expect genetic insights to drive further therapeutic 
advances, similar to how the discovery of loss-of-function PCSK9 variants 
causing hypocholesterolemia led to the development of monoclonal antibodies 
targeting PCSK9 to treat cardiovascular disease and hypercholesterolemia.69  
In our study, most of the diagnosed patients had seen a diverse array of medical 
and surgical specialists for several years prior to their diagnosis, such as primary 
care providers, internists, surgeons, endocrinologists and hepatologists, among 
others. This suggests that the investigation of unrecognized genetic disorders in 
adults would have clinical utility among a broad group of adult multispecialty 
clinical practices. Decades ago, Mendelian genetics mostly relied on family-
based studies with very distinct and often severe phenotype(s). However, as 
illustrated in this study, the absence of family history of similar phenotype should 
not deter physicians from investigating a genetic cause for the unexplained liver 
disease since it might arise from a de novo variant, which by definition is not 
inherited from any parent, or result from a recessive inheritance pattern when 
both parents are usually healthy carriers and 75% of siblings will be clinically 
unaffected. 
One limitation of this study is a relatively small sample size and patient 
recruitment at a single tertiary care academic center and affiliated community 
hospital. Further studies are required to assess the generalizability of these 
findings in a broader liver disease population. Additionally, the patients in this 
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cohort whose phenotypes remain unexplained may have a pathogenic variant not 
detected by the methodology used, such as variants in the non-coding region of 
the genome (including promoters, enhancers, silencers, miRNA, etc), or in a 
gene not yet known to be associated with a human disease. In fact, 
approximately three quarters of human genes have not yet been linked to a 
human phenotype20, and for this reason we will continue to re-analyze these 
patients’ WES data regularly. This study’s diagnostic yield is comparable to data 
recently reported in inherited cardiovascular diseases and chronic kidney disease 
in adults.29,32,33 
 
 
Figure 16: Schematic representation of multidisciplinary Genome Rounds in Adult Hepatology. It 
merges genotype-phenotype information with the goal of recognizing unappreciated phenotypic 
features by standard clinical examination, providing a diagnosis and new therapeutic options, and 
establishing adequate family counseling in adults. gDNA, genomic DNA. 
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Collectively, our data support the incorporation of WES in the diagnostic and 
management algorithms of adults suffering from idiopathic liver disease despite a 
comprehensive work-up, and underscore its value as a means of developing an 
understanding of the genetic basis of liver disease previously described as 
cryptogenic or “of unknown etiology”. A multidisciplinary Genome Rounds 
approach (Figure 16) is a likely forum from which to develop best practice 
guidelines for genomic medicine in a variety of non-oncological medical and 
surgical specialties, including hepatology. This strategy will shed further light on 
genetic contributions, and therefore underlying molecular pathogenesis, across 
different forms of liver disease that are clinically indistinguishable through 
conventional diagnostic approaches. We anticipate the diagnostic yield of WES 
to be highest in patients displaying chronic phenotypes from an early age, 
atypical clinical presentations such as lean NAFLD/NASH, the presence of 
congenital or syndromic features, a positive family history, the presence of 
consanguinity, or alternatively when WES is used to replace single gene and 
gene panel testing. 
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